Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

This is a real-world observational study tracking outcomes of patients in China who are newly diagnosed with multiple myeloma (a blood cancer) and are receiving modern immunotherapy-based treatments as their first line of care. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - You are planning to receive first-line immunotherapy at the participating center - Your treatment includes proteasome inhibitors, immunomodulatory drugs, or anti-CD38 antibodies (alone or in combination) **You may NOT be eligible if...** - You have already started treatment elsewhere - You have a different type of blood cancer - You decline to provide consent for data collection Talk to your doctor to see if this trial is right for you.